Canada Markets close in 3 hrs 13 mins

Pfizer Inc. (PFE)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
42.15+0.83 (+2.00%)
As of 12:46PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close41.32
Bid42.13 x 1800
Ask42.14 x 1200
Day's Range41.59 - 42.19
52 Week Range32.83 - 51.86
Avg. Volume32,794,835
Market Cap235.927B
Beta (5Y Monthly)0.67
PE Ratio (TTM)21.35
EPS (TTM)1.97
Earnings DateOct. 25, 2021 - Oct. 29, 2021
Forward Dividend & Yield1.56 (3.98%)
Ex-Dividend DateJul. 29, 2021
1y Target Est46.23
  • Editor's Pick
    Yahoo Finance Video

    How Johnson & Johnson’s vaccine meets the ‘gold standard’ of the WHO

    Johnson & Johnson CFO Joseph J. Wolk joins Yahoo Finance to discuss Johnson & Johnson’s recent earnings, the effectiveness of its vaccine, and the importance of innovation.

  • Simply Wall St.

    What Kind Of Shareholders Own Pfizer Inc. (NYSE:PFE)?

    If you want to know who really controls Pfizer Inc. ( NYSE:PFE ), then you'll have to look at the makeup of its share...

  • Motley Fool

    Johnson & Johnson May Not Have to Wait Long for Its Next Blockbuster Vaccine

    While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.